Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (NVUC).

Weyerer V, Weisser R, Moskalev EA, Haller F, Stoehr R, Eckstein M, Zinnall U, Gaisa NT, Compérat E, Perren A, Keck B, Allory Y, Kristiansen G, Wullich B, Agaimy A, Hartmann A, Bertz S.

Histopathology. 2019 Jul 26. doi: 10.1111/his.13958. [Epub ahead of print]

PMID:
31348552
2.

Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2).

Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R.

Oncologist. 2019 Jul 10. pii: theoncologist.2018-0280. doi: 10.1634/theoncologist.2018-0280. [Epub ahead of print]

PMID:
31292267
3.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
4.

Metastatic risk stratification of clear cell renal cell carcinoma patients based on genomic aberrations.

Grimm J, Zeuschner P, Janssen M, Wagenpfeil S, Hartmann A, Stöhr C, Keck B, Kahlmeyer A, Stöckle M, Junker K.

Genes Chromosomes Cancer. 2019 Sep;58(9):612-618. doi: 10.1002/gcc.22749. Epub 2019 Mar 28.

PMID:
30851148
5.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

6.

Online support groups offer low-threshold backing for family and friends of patients with prostate cancer.

Ihrig A, Renner T, Muck T, Maatz P, Borkowetz A, Keck B, Maatouk I, Wirth MP, Huber J.

Eur J Cancer Care (Engl). 2019 Mar;28(2):e12982. doi: 10.1111/ecc.12982. Epub 2018 Dec 20.

PMID:
30569592
7.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
8.

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.

Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

PMID:
30483954
9.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

10.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

11.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

12.

Diagnostic potential of major and trace elements in the serum of bladder cancer patients.

Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, Keck B, Hartmann A, Wullich B, Taubert H, Chaudhri A.

J Trace Elem Med Biol. 2018 Mar;46:150-155. doi: 10.1016/j.jtemb.2017.12.010. Epub 2017 Dec 28.

PMID:
29413105
13.

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.

van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC.

Clin Cancer Res. 2018 Apr 1;24(7):1586-1593. doi: 10.1158/1078-0432.CCR-17-2719. Epub 2018 Jan 24.

14.

Face-to-face vs. online peer support groups for prostate cancer: A cross-sectional comparison study.

Huber J, Muck T, Maatz P, Keck B, Enders P, Maatouk I, Ihrig A.

J Cancer Surviv. 2018 Feb;12(1):1-9. doi: 10.1007/s11764-017-0633-0. Epub 2017 Aug 31.

PMID:
28861845
15.

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.

Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium.

PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.

16.

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.

Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF.

Eur Urol. 2017 Sep;72(3):461-469. doi: 10.1016/j.eururo.2017.05.040. Epub 2017 Jun 2.

PMID:
28583312
17.

Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort.

Vetterlein MW, Meyer CP, Leyh-Bannurah SR, Mayr R, Gierth M, Fritsche HM, Burger M, Keck B, Wullich B, Martini T, Bolenz C, Pycha A, Hanske J, Roghmann F, Noldus J, Bastian PJ, Gilfrich C, May M, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 study group.

Clin Genitourin Cancer. 2017 Oct;15(5):e809-e817. doi: 10.1016/j.clgc.2017.04.021. Epub 2017 Apr 26.

PMID:
28550955
18.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

19.

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17.

PMID:
27992871
20.

Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency.

Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, Keck B, Pizzolitto S, Sioletic S, Wullich B, Hartmann A.

Am J Surg Pathol. 2017 Feb;41(2):253-262. doi: 10.1097/PAS.0000000000000787.

PMID:
27984237
21.

The effect of an online support group on patients׳ treatment decisions for localized prostate cancer: An online survey.

Huber J, Maatz P, Muck T, Keck B, Friederich HC, Herzog W, Ihrig A.

Urol Oncol. 2017 Feb;35(2):37.e19-37.e28. doi: 10.1016/j.urolonc.2016.09.010. Epub 2016 Oct 31.

PMID:
27810256
22.

Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study.

Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, Scheufele R, Wirth MP, Huber J.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):61-66. doi: 10.1038/pcan.2016.43. Epub 2016 Sep 13.

PMID:
27618951
23.

Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.

Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rödel C, Fietkau R, Wullich B, Keck B, Hartmann A.

Virchows Arch. 2016 Sep;469(3):339-44. doi: 10.1007/s00428-016-1986-x. Epub 2016 Jul 8.

PMID:
27392930
24.

How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, Krause FS, Merten R, Ott O, Fietkau R, Wullich B, Keck B.

Urol Int. 2017;98(3):262-267. doi: 10.1159/000447361. Epub 2016 Jul 5.

PMID:
27376673
25.

Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.

Agaimy A, Bertz S, Cheng L, Hes O, Junker K, Keck B, Lopez-Beltran A, Stöckle M, Wullich B, Hartmann A.

Virchows Arch. 2016 Sep;469(3):321-30. doi: 10.1007/s00428-016-1977-y. Epub 2016 Jun 23.

PMID:
27339451
26.

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.

27.

[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].

Lieb V, Rink M, Sikic D, Keck B.

Urologe A. 2016 Jun;55(6):805-12. doi: 10.1007/s00120-016-0090-9. German.

PMID:
27146873
28.

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

Sikic D, Meidenbauer N, Lieb V, Keck B.

Urologe A. 2016 Jul;55(7):952-5. doi: 10.1007/s00120-016-0089-2. Review. German.

PMID:
27146871
29.

[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].

Sikic D, Lüdecke G, Lieb V, Keck B.

Urologe A. 2016 May;55(5):648-52. doi: 10.1007/s00120-016-0088-3. Review. German.

PMID:
27119958
30.

Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.

Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich B, Keller A, Meese E.

Tumour Biol. 2016 Aug;37(8):10177-85. doi: 10.1007/s13277-016-4883-7. Epub 2016 Jan 29.

PMID:
26831660
31.

Results of Renal Transplantation on Alloplastic Arterial Grafts.

Sagban TA, Regus S, Heller K, Jacobi J, Apel H, Keck B, Richterstetter M, Eckardt KU, Wullich B, Lang W.

Urol Int. 2016;96(2):157-63. doi: 10.1159/000443213. Epub 2016 Jan 13. Review.

PMID:
26756991
32.

Long-Term Respiratory Support for Children and Adolescents in Austria: A National Survey.

Weiss S, Van Egmond-Fröhlich A, Hofer N, Pfleger A, Rath R, Schwarz R, Kurz H, Waibel V, Kenzian H, Kommer E, Wadlegger F, Stelzl W, Keck B, Grigorow I, Kerbl R, Sauseng W, Frischer T, Eber E, Bernert G.

Klin Padiatr. 2016 Jan;228(1):42-6. doi: 10.1055/s-0035-1565240. Epub 2015 Dec 23.

PMID:
26697738
33.

[Operative therapy of spinal metastases from urological tumors].

Richter RH, Hammon M, Uder M, Huber J, Goebell PJ, Kunath F, Wullich B, Keck B.

Urologe A. 2016 Feb;55(2):232-40. doi: 10.1007/s00120-015-3999-5. Review. German.

PMID:
26678798
34.

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.

Kunath F, Borgmann H, Blümle A, Keck B, Wullich B, Schmucker C, Sikic D, Roelle C, Schmidt S, Wahba A, Meerpohl JJ.

BMJ Open. 2015 Nov 13;5(11):e008217. doi: 10.1136/bmjopen-2015-008217. Review.

35.

[Vertebral metastases of urogenital carcinomas: Diagnosis and conservative therapy].

Keck B, Hammon M, Uder M, Huber J, Goebell PJ, Kunath F, Wullich B, Richter RH.

Urologe A. 2016 Feb;55(2):226-31. doi: 10.1007/s00120-015-3977-y. Review. German.

PMID:
26450096
36.

Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Goebell PJ, Schick S, Olbert P, Huber J, Wullich B, Keck B.

Anticancer Res. 2015 Jul;35(7):4277-81.

PMID:
26124390
37.

Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.

Leidinger P, Keller A, Milchram L, Harz C, Hart M, Werth A, Lenhof HP, Weinhäusel A, Keck B, Wullich B, Ludwig N, Meese E.

PLoS One. 2015 Jun 3;10(6):e0128235. doi: 10.1371/journal.pone.0128235. eCollection 2015.

38.

Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.

Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A.

Mol Med. 2015 May 13;21:371-80. doi: 10.2119/molmed.2014.00250.

39.

Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta.

Aziz A, Gierth M, Rink M, Schmid M, Chun FK, Dahlem R, Roghmann F, Palisaar RJ, Noldus J, Ellinger J, Müller SC, Pycha A, Martini T, Bolenz C, Moritz R, Herrmann E, Keck B, Wullich B, Mayr R, Fritsche HM, Burger M, Bastian PJ, Seitz C, Brookman-May S, Xylinas E, Shariat SF, Fisch M, May M; PROMETRICS 2011 Research Group.

World J Urol. 2015 Dec;33(12):1945-50. doi: 10.1007/s00345-015-1572-x. Epub 2015 May 7.

PMID:
25947885
40.

Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011.

Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, Stabenow R, Froehner M, Huber J.

Radiother Oncol. 2015 Apr;115(1):90-5. doi: 10.1016/j.radonc.2015.02.024. Epub 2015 Mar 11.

PMID:
25770874
41.

Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder.

Novotny V, Froehner M, May M, Protzel C, Hergenröther K, Rink M, Chun FK, Fisch M, Roghmann F, Palisaar RJ, Noldus J, Gierth M, Fritsche HM, Burger M, Sikic D, Keck B, Wullich B, Nuhn P, Buchner A, Stief CG, Vallo S, Bartsch G, Haferkamp A, Bastian PJ, Hakenberg OW, Propping S, Aziz A.

World J Urol. 2015 Nov;33(11):1753-61. doi: 10.1007/s00345-015-1502-y. Epub 2015 Feb 8.

PMID:
25663359
42.

Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma.

Keck B, Ellmann C, Stoehr R, Weigelt K, Goebell PJ, Kunath F, Taubert H, Hartmann A, Wullich B, Wach S.

Urol Oncol. 2014 Nov;32(8):1234-9. doi: 10.1016/j.urolonc.2014.06.016. Epub 2014 Jul 30.

PMID:
25087089
43.

[Treatment of nonmetastatic prostate cancer: a systematic review of interactive, personalized patient decision aids].

Groeben C, Streuli JC, Krones T, Keck B, Wirth MP, Huber J.

Urologe A. 2014 Jun;53(6):854-64. doi: 10.1007/s00120-014-3529-x. Review. German.

PMID:
24903837
44.

Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, Keck B, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S.

Biomed Res Int. 2014;2014:972587. doi: 10.1155/2014/972587. Epub 2014 Apr 29.

45.

Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.

Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH.

Int J Cancer. 2015 Jan 15;136(2):443-51. doi: 10.1002/ijc.28987. Epub 2014 Jun 12.

46.

Fish functional traits correlated with environmental variables in a temperate biodiversity hotspot.

Keck BP, Marion ZH, Martin DJ, Kaufman JC, Harden CP, Schwartz JS, Strange RJ.

PLoS One. 2014 Mar 27;9(3):e93237. doi: 10.1371/journal.pone.0093237. eCollection 2014.

47.

[Pharmacodynamic and pharmacokinetic characteristics of pain therapy in neonates: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Jaksch W, Messerer B, Keck B, Lischka A, Urlesberger B; Österreichischen Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin (ÖGARI).

Schmerz. 2014 Feb;28(1):25-30. doi: 10.1007/s00482-014-1389-3. German.

PMID:
24550024
48.

[Austrian interdisciplinary recommendations on pediatric perioperative pain management: background, aims, methods and key messages].

Jaksch W, Messerer B, Baumgart H, Breschan C, Fasching G, Grögl G, Justin C, Keck B, Kraus-Stoisser B, Lischka A, Mayrhofer M, Platzer M, Schoberer D, Stromer W, Urlesberger B, Vittinghoff M, Zaheri S, Sandner-Kiesling A; Österreichischen Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin (ÖGARI).

Schmerz. 2014 Feb;28(1):7-13. doi: 10.1007/s00482-013-1382-2. German.

PMID:
24550022
49.

Continental monophyly of cichlid fishes and the phylogenetic position of Heterochromis multidens.

Keck BP, Hulsey CD.

Mol Phylogenet Evol. 2014 Apr;73:53-9. doi: 10.1016/j.ympev.2014.01.011. Epub 2014 Jan 26.

PMID:
24472673
50.

Pelagic larval duration predicts extinction risk in a freshwater fish clade.

Douglas M, Keck BP, Ruble C, Petty M, Shute JR, Rakes P, Hulsey CD.

Biol Lett. 2013 Nov 6;9(6):20130672. doi: 10.1098/rsbl.2013.0672. Print 2013.

Supplemental Content

Support Center